Summary. Early pregnancy factor (EPF) is a monitor of the incidence of fertilization and the progress of the early embryo. To 
Introduction
Interplay between maternal and embryonic tissue in the preimplantation period activates systems in preparation for the successful implantation and maintenance of pregnancy. The system thought to be the first signal of pregnancy was the local endometrial reaction to the presence of the embryo, initiated by alterations in oestrogen/progesterone concentrations, detected before implantation (Beier & Mootz, 1979) . However, with the discovery of early pregnancy factor (EPF) (Morton et ai, 1974 (Morton et ai, , 1976 ), it appears that, even before this, the maternal system is being prepared immunologically for implantation of the antigenically alien conceptus (Noonan et ai, 1979) . EPF is released from the ovary in response to the presence of a conceptus as early as 4 h after fertilization (Cavanagh et ai, 1982) and has been shown to be capable of initiating pro¬ duction of suppressor factors from lymphocytes, which, in turn, can suppress certain immunological responses such as the cell-mediated (delayed-type) hypersensitivity reaction (Rolfe et ai, lymphocytes, preincubated with EPF, give a significantly higher RIT with an ALS than do lymphocytes from the same donor without EPF (Morton el a!, 1974) .
The assay was performed with spleen cells from outbred, male Quackenbush mice, rabbit anti-mouse lymphocyte serum and human red blood cells (RBC) (Rolfe et a!, 1984; Morton et a!, 1987) , with one batch of ALS used throughout. For each test, 1-8 IO7 freshly isolated spleen cells were incubated at 37°C for 0-5 h with 0-2 ml test sample. After incubation, the cells were washed twice in Hank's balanced salt solution (HBSS), reconstituted to 1 0 ml in HBSS and used to estimate the RIT of an ALS as described by Rolfe et al. (1984) . Positive Polyclonal anti-EPF IgG was also prepared against mouse EPF for use in screening hybridoma supernatants for anti-EPF specificity by a two-site immunoradiometric assay (IRMA). Two rabbits were immunized with 4 monthly injections of mouse EPF (1 pg in Freund's adjuvant/injection) and the serum was tested for anti-EPF activity by RIA, as described above, with human EPF on the solid phase. Rabbit 802, which gave results > 5 times the control value, was selected.
IgG was isolated from rabbit serum by precipitation with 18% sodium sulphate (Johnstone & Thorpe, 1987a) , followed by chromatography on DEAE Affi-Gel Blue (Bio-Rad, Richmond, CA, USA), using 20 mM-Tris-HCl, pH 8-0/28 mM-NaCl/0-01% sodium azide as elution buffer, according to the manufacturer's instructions. The final preparation was analysed by SDS-PAGE (Gorg et a!, 1981) , protein concentration was determined (Lowry et a!, 1951) and anti-EPF specificity was confirmed by RIA, as (Goding, 1986a 20 (to separate antigen-antibody complexes), mixed at 4°C for 0-5 h and passed through an activated C18 Sep-pak (Waters Assoc, Milford, MA, USA) which binds EPF. The flow-through fraction containing Ig was collected, the pH raised to 80 with solid Tris, dialysed against 005 M-sodium phosphate buffer, pH 7-4/0-15 mNaCl (PBS)/0-01 % (w/v) sodium azide overnight at 4°C and concentrated to 0-2 ml using a Centricon Micro concen¬ trator (Amicon, Danviers, MA, USA).
Screening supernatants for anti-EPF specificity. Treated supernatants were tested for anti-EPF specificity by (i) the rosette inhibition test and (ii) IRMA. In (i) after treatment as above, a sample of supernatant was dialysed against PBS, then incubated (01 ml, 1/10 in PBS, 37°C, 0-5 h) with mouse EPF (0-1 ml, 5-0 ng/ml in HBSS/0-01 % BSA). Control tests were mouse EPF incubated with (a) PBS and (b) with rabbit (No. 802) anti-EPF IgG (01 ml, 0-5 pg/ml in PBS). After incubation, the mixtures were tested for activity in the rosette inhibition test; a negative result (i.e. RIT < 16) was considered evidence of the presence of anti-EPF Ig.
(ii) As more purified human EPF became available, a modified IRMA (Johnstone & Thorpe, 1987b ) was used to confirm specificity of selected positive wells; this assay was used due to the low affinity binding of the anti-EPF monoclonals. Ig in treated supernatants was bound to sheep anti-mouse IgG on a solid phase, as described above. Control tests consisted of anti-EPF mouse serum from immune spleen donors (1/1000 in diluting buffer; positive) and culture medium (negative). The tests were incubated overnight at 4°C with human EPF (01 ml, 10 pg/ml in diluting buffer), then rabbit (No. 802) anti-mEPF IgG (0-1 ml, 10 pg/ml in diluting buffer) was added to the washed tubes (3 h, 37°C). Bound rabbit IgG was detected as previously described. A result >2-5 times the result with culture medium alone was considered positive for anti-EPF (Goding, 1986b (Goding, 1986c) . Ascitic fluid was treated at pH 2-5 with glycine-HCl followed by passage through a Sep-pak cartridge to remove EPF (see above). IgM was precipitated during dialysis against 5 mM-Tris-HCl buffer, pH 7-5 at 4°C overnight (Goding, 1986d) , reconstituted in PBS/001% sodium azide, protein concentration measured (Lowry et a!, 1951) and the purity of the preparation analysed by SDS-PAGE (Gorg et (Fig. 1) . Similar results were obtained with the polyclonal IgG (Fig. 1) (Fig. 2a) . The average number of embryos in the test groups of mice that remained pregnant did not vary significantly from that in the control groups (Fig. 2a) . Polyclonal anti-EPF IgG. Administration of anti-EPF polyclonal IgG from Rabbits 816 and 810 resulted in only 2/7 (28-5%) and 1/6 (17%) respectively, of the mice maintaining their pregnan¬ cies. The number of mice maintaining their pregnancies in the test groups was significantly different from that in the control groups receiving rabbit IgG or saline, in which pregnancy continued in all 4 (100%) and all 5 (100%) respectively of the mice studied (Fig. 2b) . In the one mouse remaining pregnant after treatment with IgG from Rabbit 810, only 8 viable embryos were present at autopsy at 10 days gestation, compared with an average of 15 embryos per mouse in the control groups.
Discussion
Since EPF was first described as a pregnancy-associated substance, present in serum of mice within 6 h of fertile mating (Morton et ai, 1976) , many groups have carried out investigations to deter¬ mine whether EPF can be used as a marker for early pregnancy in humans and animals. EPF has been found in serum within 4-48 h offertile mating (Morton et ai, 1979; Rolfe, 1982; Koch et ai, 1983; Sueoka et ai, 1988) , or within 12^18 h after embryo transfer (Chen et ai, 1985; Morton et ai, 1987) ; the continuation of pregnancy can be monitored by following serum EPF values (Morton et ai, 1976 (Morton et ai, , 1977 (Morton et ai, , 1983 Tinneberg et ai, 1984; Qin & Zheng, 1987; Sueoka et ai, 1988) . Furthermore, after death or loss of the conceptus, EPF is no longer detectable in serum (Koch et ai, 1982; Rolfe, 1982; Qin & Zheng, 1987) ; indeed, in humans after therapeutic abortion, disappearance of EPF is the earliest marker of embryonic loss (Mettler et ai, 1985) . Taken together, these studies closely link EPF with the fate of the embryo.
The ability of EPF to monitor embryonic viability raised the possibility that it may have a role in maintaining this viability. Therefore, it was planned to prepare a number of monoclonal anti¬ bodies for use in passive immunization studies, to determine whether neutralization of EPF in vivo affected pregnancy. During the preparation of anti-EPF monoclonal antibodies, we encountered a number of very interesting problems. Initially, all the anti-EPF monoclonals produced were IgM, possibly because a low dose of immunogen was administered. Most of the anti-EPF producing hybridomas failed to grow in vitro while those that did grow produced only low yields of specific IgM antibodies. By increasing the immunizing dose of EPF, hybridomas producing IgG mono¬ clonals were prepared but these also failed to survive in culture.
The results may be explained by recent studies in our laboratory which have shown that EPF is produced not only by embryonic cells but also by actively-dividing tumour cells including myeloma and hybridoma cells. As well as producing EPF, these cells appear to require EPF for their con¬ tinued survival. These findings can be likened to those of Matsuda et ai (1988) , who reported that efforts to obtain murine hybridomas, producing monoclonal antibodies specific for human interleukin 6 (IL/6; cell stimulatory factor 2, BSF-2; hybridoma growth factor, HGF; Sugasawara, 1988) , were not successful unless recombinant IL-6 was added directly after cell fusion. A partial A'-terminal amino-acid sequence of purified human EPF (unpublished data) The function of EPF is still unclear but the effect of anti-EPF on hybridoma growth suggests that EPF may act as a growth factor and be required directly by the embryo for growth and development. To determine whether EPF has a direct influence on embryonic survival, an in-vitro system will be studied, following the protocol of Hill et ai (1987) . Monoclonal anti-EPF will be added to mouse embryo cultures and the effect on the development of the mouse embryo from the two-cell stage through to the blastocyst stage will be observed.
On the other hand, EPF may act indirectly by initiating systems in vivo which are important to the survival of the embryo. It has been postulated that suppressor factors, induced by EPF (Rolfe et ai, 1988) , may play a role in the prevention of maternal anti-fetal reactions at the time of implantation, when the implanting blastocyst comes in close contact with the maternal circulation. Beaman & Hoversland (1988) have shown that passive immunization of mice on Days 2 to 6 with m Ab 14-30, a monoclonal antibody which binds T-cell-produced suppressor factors, results in embryonic loss. Whether these suppressor factors are related to those induced by EPF has not yet been determined but the results suggest that loss of suppressor induction following EPF neutraliz¬ ation may be a contributing factor in the failure to maintain pregnancy. Evidence against the possibility that any antibody-antigen reaction within the genital tract/uterus will lead to termina¬ tion of pregnancy has been provided by Sulila et al. (1988) , who showed that passive immunization with a rat monoclonal antibody to the T-cell surface molecule CD8, while depleting the population of CD8-positive lymphocytes, did not affect the outcome of pregnancy.
From the studies presented in this paper, it can be concluded that, since neutralization of EPF results in embryonic loss, EPF, whether directly or indirectly, is a necessary element in the complex interplay of events leading to the successful establishment of pregnancy.
